The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-Despite cardioprotective properties, studies investigating adiponectin as a cardiovascular disease marker led to conflicting results. We investigated in participants with stable coronary artery disease (CAD) and controls whether serum adiponectin was associated with long-term mortality, considering varying degrees of CAD severity.
A diponectin is the most abundant protein secreted from adipose tissue. 1 In animal and in vitro models, adiponectin displays insulin-sensitizing, 2 anti-inflammatory, 3, 4 antithrombotic, 5 antiatherogenic, 4, 6, 7 and cardioprotective properties. 3, 8 Adiponectin is abundant in plasma, and its concentration is decreased in patients with obesity, 1 type 2 diabetes mellitus, 9 metabolic syndrome, 10 and coronary artery disease (CAD). 11 A high serum adiponectin level is associated with a favorable cardiovascular risk profile.
Previous epidemiological studies investigating adiponectin as a cardiovascular disease (CVD) marker led to conflicting results. A low serum adiponectin level was associated with an increased risk of CVD in patients with familial dyslipidemia 12 and diabetes mellitus, 13 but also among healthy people. [14] [15] [16] Conversely, in other studies, a high serum adiponectin level was associated with a rise of CVD in blacks 17 and elderly people. 18 Results were more homogeneous when the relationship between adiponectin and mortality risk was investigated. Paradoxically, a high serum adiponectin level was associated with an increased mortality risk from all causes and from CVD in healthy people, [19] [20] [21] as well as in patients with CAD, [22] [23] [24] [25] [26] heart failure, 21, 27, 28 renal insufficiency, 29 or type 1 diabetes mellitus. 30 The underlying mechanisms of the association among adiponectin, cardiovascular risk, and mortality still remain to be elucidated. In the present study, we further investigated whether serum adiponectin level was associated with long-term mortality from all causes and from CVD, considering varying degrees of CAD severity, both among control men without CAD and in men with stable CAD, originating from the same population.
Materials and Methods

Study Population
The Genetique et ENvironnement en Europe du Sud (GENES) study is a case-control study designed to investigate the role of gene-environment interaction in the occurrence of CAD. As previously described, 31 from 2001 to 2004, we prospectively recruited 791 men aged between 45 and 74 years, living in the Toulouse area (Southwestern France), admitted in the Department of Cardiology of the Toulouse University Hospital and referred for evaluation and management of stable CAD. Stable CAD was defined by a previous history of acute coronary syndrome, a previous history of coronary artery revascularization, a documented myocardial ischemia, a stable angina, or the presence of a coronary stenosis of ≥50% of luminal narrowing at the coronary angiography. Patients who had an acute coronary episode during the past 7 days were not included in the study because they were not considered as stable. During the same period, 820 male controls, aged 45 to 74 years, were selected from the general population using the electoral rolls. Stratification by 10-age group was used to approximately match the age distribution of the controls with that of cases.
The study protocol was approved by the local ethics committee (file 1-99-48, February 2000) and the national commission for data processing and freedoms (N° 900165). A biological sample collection has been constituted (declared as DC-2008-403 1 to the Ministry of Research and to regional health authority).
In the present analysis, we only took into account the first 715 patients and 782 controls in whom total serum adiponectin was measured and complete data were available for all the subjects. Vital status was obtained in June 2011 for each participant through the French national database recording all deaths occurring in the French population. All-cause mortality and specific causes of death were available until December 2010. 32 Death certificates were checked for supporting clinical and postmortem information on cause of death. A medical committee including 2 medical doctors and 2 epidemiologists was established to examine medical data related to all deaths. The first outcome analyzed was all-cause mortality, and the second outcomes were cardiovascular mortality (including sudden cardiac death) and noncardiovascular mortality.
Male controls underwent medical examination in the same health center administered by the national health insurance system and located approximately in the center of the area studied. Similarly, male cases were examined in the Department of Cardiology in the Toulouse University Hospital during the same period. Inclusion started with providing oral and written information about the aim of the study, and informed consent was signed. The medical examination took ≈120 minutes. Medical examination included clinical and anthropometric measurements and was followed by the completion of a questionnaire (lasting for ≈40 minutes). Blood samples were taken, and a blood sample collection was constituted.
Data Collection
Age, socioeconomic variables, educational level (number of years spent at school), and information on cardiovascular risk factors were collected through standardized face-to-face interviews, performed by a single physician. Smoking status was classified as current smokers, smokers having quitted for >3 months, and nonsmokers. Among current smokers, cigarette consumption was estimated with the packyear quantification. Alcohol consumption was assessed using a typical week pattern. The total amount of pure alcohol consumed was calculated as the sum of different types of drinks and was expressed as grams per day. Physical activity was investigated through a standardized questionnaire 33 and categorized into 3 levels: no physical activity; moderate physical activity during 20 minutes no more than once a week; and intense physical activity during 20 minutes, at least twice a week. Presence of dyslipidemia, diabetes mellitus, or hypertension was assessed from the subjects' current treatments. Medical history was collected through a standardized questionnaire and was also checked in the patients' medical files for cases. Medications at discharge were also considered in patients.
Physical examinations were performed by a trained physician and using standard measurement methods. Anthropometrical measurements, including waist circumference, height, and body weight, were performed according to standardized procedures. Body mass index was calculated as weight divided by height squared (kg/m²). Blood pressure and resting heart rate were measured with an automatic sphygmomanometer (OMRON 705 CP) using a cuff size fitted to the upper arm perimeter. Right arm blood pressure and heart rate were measured twice, and the average values were recorded for the analysis. Measurements were performed after a minimum of 5-minute rest. Ankle brachial index was determined as previously described, and value ≤0.9 was considered abnormal. 34
Assessment of CAD Severity and Estimation of Cardiac Function in Patients
Coronary artery stenosis ≥50% of luminal narrowing was considered significant. Diffusion of coronary heart disease lesions was assessed by calculating the Gensini score, the Duke-Jeopardy score, and the number of coronary arteries with at least 1 significant lesion, without considering the left main artery and a CAD severity score previously described and based on data from a standard coronary angiography. [35] [36] [37] Left ventricular ejection fraction (LVEF) was assessed by contrast ventriculography or by isotopic method and echocardiography.
Blood Sampling and Laboratory Methods
Blood was collected after an overnight fast. Serum sample aliquots were subsequently stored at −80°C until biological analyses. Biological measurements were performed in a core laboratory in the Toulouse University Hospital. The following biomarkers were assayed with enzymatic reagents on an automated analyzer (Hitachi 912; Roche Diagnostics, Meylan, France): serum total cholesterol, high-density lipoprotein (HDL) cholesterol, serum triglycerides, blood glucose, γ-glutamyltransferase, and high-sensitive C-reactive protein (hs-CRP). Apolipoprotein A1, apolipoprotein B, and lipoprotein (a) were assayed with an immunoturbidimetric method on an automated analyzer (Roche Diagnostics). Serum insulin was measured with a sandwich enzyme immunoassay using direct chemiluminescence (Advia Centaur; Siemens Healthcare Diagnostics, Cergy-Pontoise, France). The estimated glomerular filtration rate was calculated using the abbreviated modification of diet in renal disease study equation. 38 Insulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR). 39
Measurements of Adiponectin
Serum adiponectin concentrations were measured with Total Adiponectin/Acrp 30 Quantikine ELISA kit (R&D Systems, Abingdon, United Kingdom). Serum samples were diluted 1:100 before measurements. Performance characteristics of this assay include a minimal detectable concentration of 0.25 ng/mL, corresponding to 0.025 µg/mL in undiluted serum. Intra-assay precision and interassay reproducibility measurements gave coefficients of variation <5% and 7%, respectively, in the concentration range tested from 20 to 150 ng/ mL (corresponding to 2-15 µg/mL in undiluted serum). Laboratory technicians performing the assays were blinded to treatment allocation and clinical outcome.
Statistical Analysis
Continuous variables were displayed as means and SDs. Categorical variables are presented as proportions. In univariate analysis, qualitative variables were compared with χ 2 test (or Fisher exact test when necessary). Mean values of quantitative variables were compared by the Student t test. The Shapiro-Wilks and the Levene tests were used to test the normality of distribution of residuals and the homogeneity of variances, respectively. When basic assumptions of the Student t test were not satisfied, a logarithmic transformation of the variables was done or a Wilcoxon-Mann-Whitney test was performed.
Cumulative survival of patients and controls according to quartiles of plasma adiponectin levels was determined by the Kaplan-Meier method and compared using the log-rank test for the individual end points of all-cause mortality, cardiovascular-related mortality, and noncardiovascular-related mortality. The relationship between baseline variables and mortality was assessed using Cox proportional hazards regression analysis. We tested the proportionality assumption using cumulative sums of martingale-based residuals. 40 We performed regression analyses with polynomial models (quadratic and cubic) to examine for possible nonlinear relationships between continuous variables and mortality. Considering controls and total mortality, all variables associated with a P<0.20 in univariate analysis were introduced in a multivariate Cox model. A backward procedure was applied to assess variables that were significantly and independently associated with mortality (P<0.05). The same variables selected for all causes of death were used to perform adjustment for CVD and non-CVD mortality. Similarly, analytic procedures were performed for CAD patients, for the group combining cases and controls, and finally for the control group after exclusion of subjects treated with oral hypoglycemic agents, insulin, β-blockers, angiotensin-converting enzyme inhibitors, and subjects with an ankle-arm index ≤0.9. Two variables (body mass index and blood glucose) were forced into the final models when they remained not significantly associated with mortality after selection procedure. The ability of each model to discriminate mortality was quantified by calculating the integrated discrimination improvement index 41 in CAD patients, controls, and the whole population. Integrated discrimination improvement was quantified after inclusion of adiponectin in the classical risk factor model. 41, 42 All statistical analyses were carried out using the SAS statistical software package 9.2 (SAS Institute, Cary, NC). All tests were considered significant at a P<0.05.
Results
Complete data were available for 715 CAD patients and 782 age-stratified controls, recruited between 2001 and 2004. On December 31, 2010, the median follow-up was 8.1 years (range, 9.2 years). During the follow-up period, 148 deaths (20.7%) occurred in the group of CAD patients, of which 95 (64.2%) deaths were related to CVD disease. In the mean time, 45 deaths (5.7%) were recorded in the control group, of which 22 (48.9%) deaths were related to CVD disease. Among survivors, follow-up duration was similar in cases (8.4±0.7 years) and controls (8.1±0.8 years).
Baseline Characteristics
Baseline demographic data, clinical variables, laboratory metabolic variables, and angiographic characteristics are summarized in Table 1 for CAD patients, considered both as whole populations and by quartiles of adiponectin (Q1+Q2+Q3 versus Q4), and similarly for controls. The third quartile of the adiponectin distribution was 7.3 µg/mL in CAD patients, 9.1 µg/mL in controls, and 8.2 µg/mL in both cases and controls. Except for alcohol consumption and resting heart rate, differences between cases and controls were statistically significant. The mean age of CAD patients was 60.2±8.0 years. CAD patients had a high-risk cardiovascular profile, with 82.5% of current or former smokers, 24.8% of patients with diabetes mellitus, 44.6% of patients under treatment for hypertension, and 64.9% under treatment for dyslipidemia. In controls, the mean age was 59.0±8.3 years. The control group included 65.6% of past or current smokers, 5.7% of patients with diabetes mellitus, 20.2% of subjects under treatment for hypertension, and 22.9% of people under treatment for dyslipidemia. Regarding all those parameters, differences between cases and controls were highly significant. Compared with participants in their respective lowest quartiles, CAD patients and controls in the highest plasma adiponectin quartiles were older, whereas no significant difference was noted with regard to smoking, alcohol consumption, physical activity, and educational level. Although no significant difference was noted with regard to prevalence of hypertension and diabetes mellitus treatment, the proportion of patients under treatment for dyslipidemia was lower in those with higher adiponectin levels, and a similar trend was observed for controls (P=0.07).
Patients and controls with higher adiponectin had a better metabolic profile with higher HDL and apolipoprotein A1 levels and lower body mass index, waist circumference, lower triglyceride and apolipoprotein B concentration, lower insulin level, and HOMA-IR value.
Among CAD patients, 26% displayed an LVEF <50% and 33.8% had a pejorative value (≤0.9) of the ankle-arm index, suggestive of subclinical peripheral arterial disease. Patients in the highest adiponectin quartile had significantly more LVEF (P<0.001) and more peripheral arterial disease (P=0.02). Among CAD participants, no significant difference was observed according to adiponectin quartiles, regarding coronary artery atherosclerosis as estimated by the Gensini score, the number and severity of stenosis, and the Duke-Jeopardy scores. The duration of existing CADs was significantly higher at high adiponectin levels. The resting heart rate was higher (P<0.001) in the highest quartile of serum adiponectin in CAD participants, whereas such gradient was not observed in controls.
Spearman rank correlation coefficients between serum adiponectin and metabolic parameters in CAD participants, controls, and the whole population are available in Table 2 . In the whole population, serum adiponectin was significantly positively correlated with total cholesterol, HDL cholesterol, and apolipoprotein A1. Serum adiponectin was inversely correlated with body mass index, waist size, serum insulin, fasting glucose, triglycerides, apolipoprotein B, hs-CRP, and HOMA-IR.
Adiponectin Concentration and Risk of CAD
Before adjustment, mean serum adiponectin level was significantly lower in CAD participants than in controls (P<0.001). Unadjusted means and SEM were 5.6±0.2 and 7.1±0.2 µg/mL respectively. After multivariate adjustment for diabetes mellitus, dyslipidemia, and hypertension, systolic blood pressure, resting heart rate, tobacco consumption, hs-CRP, HDL cholesterol, lipoprotein (a), ankle-arm index, and physical activity, adjusted means were similar in cases (6.1±0.3 µg/mL) and controls (6.5±0.3 µg/mL; P=0.13).
Survival Analysis
During the follow-up period (median, 8.1 years), the cumulative mortality rate was 5.7% (95% CI, 4.2-7.7%) in controls and 20.7% (95% CI, 17.8-23.9%) in CAD participants. Kaplan-Meier survival curves in CAD participants according to quartiles of adiponectin are presented in Figure 1 . At the end of the follow-up period, the survival rate was 67.6% in CAD patients with adiponectin ≥7.3 µg/mL (75th percentile), 76.4% in patients with adiponectin between 4.5 and 7.3 µg/ mL, 85.6% in patients with adiponectin between 2.7 and 4.5 µg/mL, and 87.5% in patients with adiponectin <2.7 µg/mL (25th percentile; log-rank test P<0.001). A comparable highly significant gradient according to adiponectin levels was observed for cardiovascular-related deaths (log-rank test P<0.001) and also for non-CVD-related mortality (log-rank test P=0.04). In controls, at the end of the follow-up period, the survival rate was 91.0% in participants with adiponectin ≥9.1 µg/mL (75th percentile) and 95.3% in subjects with adiponectin <9.1 µg/mL (log-rank test P=0.035). This trend was found to be highly significant in CVD-related mortality but not in non-CVD-related deaths (Figure 2 ). Comparisons of variables associated with all-cause mortality in CAD participants and controls are presented in Table 3 . In CAD patients, the following parameters were found to be associated with mortality: high serum adiponectin, older age, tobacco consumption, low physical activity, treatment for diabetes mellitus or dyslipidemia, low serum apolipoprotein A1 and triglycerides, low estimated glomerular filtration rate, high hs-CRP, γ-glutamyltransferase, hyperglycemia, low ankle-arm index, high heart rate, low LVEF, high Gensini score, and long duration of CAD. In controls, analyses identified the following variables as associated with mortality during follow-up: older age, tobacco consumption, treatment for hypertension and elevated systolic blood pressure, high waist circumference, high serum insulin and HOMA-IR index, high hs-CRP, high resting heart rate, and low ankle-arm index. Mean adiponectin concentrations were not different between dead and alive controls.
Hazard ratios (HRs) for the association between serum adiponectin levels and all-cause mortality, CVD-related mortality, and non-CVD-related mortality before and after multivariate adjustments for potential confounding factors in CAD patients, controls, and the whole study population are presented in Table 4 . In CAD patients, serum adiponectin level ≥7.3 µg/mL (75th percentile) was significantly associated with an increase in the risk of all-cause mortality (HR=1.71 [95% CI, 1.16-2.52]; P=0.007) and of CVD-related mortality (HR=1.86 [95% CI, 1.11-3.13]; P=0.02) after multiple adjustments for major cardiovascular risk factors and metabolic parameters. Serum adiponectin level ≥7.3µg/L was associated with an increased risk of non-CVD-related mortality after univariate analysis only (HR=1.92 [95% CI, 1.06-3.47]; P=0.03) but not anymore after multivariate adjustment (HR=1.57 [95%, CI 0.79-3.10]; P=0. 20) . In the final model, tests of interaction between adiponectin and LVEF and between adiponectin and resting heart rate were not significant. In controls, serum adiponectin level ≥9.1 µg/mL (75th percentile) was significantly associated with an increase in the risk of all-cause death (HR=2.20 [95% CI, 1.15-4.22]; P=0.02) and of CVD-related mortality (HR=3.98 [95% CI, 1.43-11.1]; P=0.009) after multiple adjustment. However, a high serum adiponectin level was not associated with an increased risk of non-CVD-related mortality neither in univariate (P=0.72) nor in multivariate analyses (P=0.68). Considering the whole study population (cases and controls), multivariate analysis indicated that serum adiponectin ≥8.2 µg/mL was significantly associated with an increase in the risk of total mortality (HR=2.07 [95% CI, 1.48-2.90]; P=0.001) and cardiovascular mortality (HR= 2.93 [95% CI, 1.85-4.64]; P=0.001) but not of non-CVD-related mortality (P=0.20). An increase of 1 µg/mL in adiponectin was associated with an increased risk of total mortality of 9.0% (HR=1.09 [95% CI, 1.05-1.14]; P<0.001) in combined CAD participants and controls. Tests for interaction between controls and CAD participants for the relationships of adiponectin with mortality, CVD mortality, and non-CVD mortality were not significant. After exclusion in controls of subjects treated with oral hypoglycemic agents or insulin (n=43), β-blockers (n=25), angiotensin-converting enzyme inhibitors (n=30), and subjects with an ankle-arm index ≤0.9 (n=11), serum adiponectin remained significantly associated with CVD mortality after multivariate adjustment (HR=3.03 [95% CI, 1.04-8.81]; P=0.04). The increase in integrated discrimination improvement was 1.5±0.6% (P=0.006) and 1.3±0.6% (P=0.04) for total mortality and CVD mortality, respectively, in patients, 
Discussion
In the present study including well-characterized 715 stable CAD male participants and 782 male controls, we demonstrate that adiponectin is a predictor of total and CVD mortality in CAD participants but also in control subjects without known CAD. We also observed that adiponectin level was lower in CAD participants compared with controls in unadjusted analysis. Contrary to a previous study of Kumada et al, 11 this result was no more significant after extensive adjustment for confounding factors but was in agreement with our previous work. 43 Many positive associations between adiponectin and metabolic parameters (total cholesterol, HDL cholesterol, and apolipoprotein A1) were observed. Conversely, serum adiponectin was inversely correlated with body mass index, waist circumference, serum insulin, fasting glucose, serum triglycerides, apolipoprotein B, hs-CRP, and HOMA-IR. The relationships of adiponectin with various metabolic factors reflect the classical association between low adiponectin and metabolic syndrome. 1, 9 Our study provides further evidence for the paradoxical observation that lower serum adiponectin is associated with a worse metabolic profile, a worse cardiovascular risk profile, and presence of CAD, but low serum adiponectin level is also related to a better outcome both in CAD participants and in people without known CAD, even after adjustment for metabolic parameters.
A left ventricular dysfunction was noted in 26% of the CAD participants and 50% of CAD participants who died. Adiponectin was higher in participants with left ventricular dysfunction, as previously reported, and was associated with a worse outcome. 27, 28 The relationship between adiponectin and mortality remains significant after adjustment for LVEF, at a variance with another study by Maiolino et al. 24 However, the strength of the relationship slightly decreased after multivariate adjustment. Other parameters of the severity of CAD, such as the Gensini score, peripheral arterial disease, and resting heart rate, were all associated with mortality. In our study, adiponectin significantly maintained its association with mortality, whatever the severity of the disease at variance by Beatty et al 25 and Cavusoglu et al. 22 Other studies have also demonstrated this relationship in patients with unstable CAD or acute coronary syndrome. 22, 26, 44 Overall, our study provides new evidence that in stable CAD patients, high adiponectin level is associated with an increased risk of all-cause mortality and CVD mortality, whatever the severity of the disease. High serum adiponectin level was also significantly associated with total and CVD-related mortality in male participants without known CAD. It remained positively and significantly associated with mortality after multivariate adjustment and also when participants treated by β-blockers, angiotensinconverting enzyme inhibitors, insulin or oral hypoglycemic agents, and subjects with ankle-arm index ≤0.9 were excluded. The relationship between adiponectin and cardiovascular mortality remained significant in this stricter control group at low risk of subclinical atherosclerosis, suggesting that it cannot be fully related to atheromatous disease.
Adiponectin was suspected to be associated with mortality related to cancer and also to non-CVD-related and noncancer-related mortality. 45, 46 It has been suggested that adiponectin could be involved in the development, the progression, and the prognosis of several malignancies. 47, 48 We have not observed this association in controls (however, the number of deaths from cancer was small), but HRs were very close to 1. However, in CAD participants, in univariate analysis, a significant association between high adiponectin level and non-CVD mortality was observed, which lost significance after multivariate adjustment, particularly for age and tobacco consumption.
Adiponectin levels are different according to the geographic origin of subjects. 17, 49 Our study included only CAD participants and controls from the Southwestern part of France generally characterized by a low CVD mortality and a low CAD incidence. 50 The positive association of adiponectin and mortality in this population at low-risk remains significant as well.
Only a few studies are currently available, including wellcharacterized CAD participants and controls. Pilz et al 23 described a similar relationship between high adiponectin and mortality among 2473 CAD patients but not among 673 controls without angiographic CAD. In a population-based cohort study in The Netherlands, 45 high adiponectin was associated with poor outcome both in CAD participants and in controls only after multivariate adjustment. 45 In a prospective cohort study of 4046 older English men, high adiponectin levels were associated with increased all-cause and CVD mortality in those with heart failure and those free of CVD, but not in those with CVD without heart failure. 21 Given these heterogeneous observations, our study provides new evidence for the relationship between high adiponectin and CVD mortality in CAD participants and also in people without CAD after adjustments for confounding variables, including metabolic status and parameters of CAD severity. The lack of interaction among adiponectin, the casecontrol design, and mortality means that the prognostic value of adiponectin is not different among people with or without CAD. Therefore, our study supports the view that the worse outcome associated with high adiponectin is not related to previous CAD.
The paradox of adiponectin, a protein displaying insulinsensitizing, anti-inflammatory, antiatherogenic, and cardioprotective effects, being associated with increased risk of all-cause mortality and CVD-related mortality has been referred to as reverse epidemiology. 25 Two hypotheses have been proposed. First, adiponectin would be a marker of severity of CVD. People with greater disease severity would have greater secretion of adiponectin in an attempt to compensate the underlying effects of CAD. Adiponectin would be upregulated as a counter-regulatory mechanism to protect the vessels and heart against further inflammation, atherosclerosis, hypoxia-reoxygenation lesions, and by stimulating angiogenesis in response to tissue ischemia. 3, 22, 25, 51 This hypothesis was supported by the results of Beatty et al, 25 in which the association between higher concentrations of serum adiponectin and mortality among patients with existing CAD was no more significant after adjustment for parameters of severity of CAD. Our results do not support this hypothesis of a compensatory mechanism. Serum adiponectin levels were lower in CAD patients in univariate analysis. The relationship between high serum adiponectin and mortality was also strong in controls without CAD, and the relationship between high serum adiponectin and mortality among CAD patients remains significant after adjustment for multiple parameters of CAD severity. Second, animal models suggested the concept of adiponectin resistance as an alternative hypothesis. [52] [53] [54] In humans, Van Berendoncks et al 55 demonstrated that despite increased adiponectin expression in the skeletal muscle, patients with congestive heart failure are characterized by downregulation of adiponectin receptors. These data suggest functional adiponectin resistance in congestive heart failure at the level of adiponectin receptor gene expression. 55 Although not demonstrated at the moment, adiponectin resistance in vessels and heart might explain why elevated adiponectin is associated with a worse outcome. Adiponectin resistance might be the clue to explain those paradoxical results.
Our study has some limitations. First, it was conducted in an exclusively male population between 45 and 74 years of age. However, our study population was a large populationbased sample of controls and CAD participants, recruited in daily clinical practice, extensively documented, and providing sufficient statistical power and length of follow-up to prove the multivariable-adjusted associations between adiponectin and all-cause mortality and CVD-related mortality. Women have higher serum adiponectin levels. 1 Sex-specific differences in adiponectin limit the extent of our results to women, although the relationship between high serum adiponectin and mortality has also been reported in women. 45 Second, the assay used in our study measured total serum adiponectin levels, and we were therefore unable to estimate the levels of the various isoforms of adiponectin and their respective prognostic values. Third, the design of our study is observational. Although participants' variables were extensively described, the associations demonstrated in our work between adiponectin and mortality may be because of unmeasured confounding factors. Changes in baseline treatment occurring during follow-up, which we could not assess, might also have impacted outcome. Given the lack of longitudinal biological measurements, we were also unable to study the relationship between changes in adiponectin levels and outcome. Kizer et al 56, 57 have already demonstrated that adiponectin levels increase over time in long-lived adults and that baseline adiponectin level and longitudinal increases in the concentrations of adiponectin were independent predictors of all-cause mortality.
Finally, this observational study cannot elucidate the complex pathophysiological mechanisms behind the relationship between adiponectin and mortality. Further experimental studies are needed to explore the underlying mechanism of adiponectin function and development of adiponectin resistance before development of adiponectin-based therapeutics. However, biological active recombinant adiponectin proteins are already in development. In animals, replenishment of recombinant adiponectin or transgenic adiponectin can reverse obesity-related pathological conditions. Although there is currently no direct clinical evidence demonstrating that adiponectin is effective in treating obesity-related cardiometabolic diseases, therapeutic benefits of several antidiabetic and cardiovascular drugs, such as the agonists of peroxisome proliferator-activated receptor γ and α and statins, are associated with increased plasma adiponectin in humans. 58 Thus, adiponectin might emerge as a promising target for the development of new drugs in the field of metabolic disorders and cardiovascular diseases.
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